Soligenix Inc — Cash Flow (NASDAQ:SNGX)

Financials

Cash from operating activities -11.45 M-11.74 M-12.65 M-8.6 M-8.4 M-10.27 M -10.27 M Cash from investing activities -7 147-11.79 K-13.07 K-13.07 K—-5 883 — Cash from financing activities 24.68 M19.06 M76.82 K3.66 M7.76 M10.39 M 10.39 M Free cash flow -11.46 M-11.75 M-12.66 M-8.6 M-8.4 M-10.27 M -10.27 M

News

Soligenix receives UK regulatory designation for Behçet’s drug

Soligenix receives positive EMA opinion for orphan drug status

Soligenix stock rises after positive Behçet’s Disease treatment data

Soligenix reports positive results from SGX945 trial for Behçet’s disease

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Soligenix (NASDAQ:SNGX)

Soligenix reports positive results from psoriasis gel treatment trial

First patient dosed in Synairgen’s global phase 2 INVENT study

Soligenix hits enrollment target for CTCL treatment interim analysis

Soligenix updates medical advisory board for lymphoma treatment

Soligenix stock soars after DMC confirms safety in Phase 3 CTCL study

Soligenix reports safety milestone in phase 3 CTCL treatment trial

Soligenix expands European medical advisory board for lymphoma treatment